<DOC>
	<DOC>NCT02960893</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy of BHV-4157 versus placebo on ataxia symptoms in subjects with spinocerebellar ataxia (SCA).</brief_summary>
	<brief_title>Trial in Adult Subjects With Spinocerebellar Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<criteria>Subjects with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3 (A Maximum of 12 patients will be enrolled with this genotype FEB 1 2017 THIS CAP HAS BEEN MET FOR SCA3), SCA6, SCA7, SCA8 and SCA10 Ability to ambulate 8 meters without assistance (canes and other devices allowed) Screening total SARA total score â‰¥8 Determined by the investigator to be medically stable at baseline/randomization and must be physically able and expected to complete the trial as designed Subjects must have adequate hearing, vision, and language skills to perform SARA ratings, 8 Meter Walk Test and other neuropsychiatric testing and interviews as specified in the protocol Any medical condition other than one of the hereditary ataxias specified in the inclusion criteria that could predominantly explain or contribute significantly to the subjects' symptoms of ataxia MMSE score &lt; 24 SARA total score of &gt; 30 points at screening Clinical history of stroke Active liver disease or a history of hepatic intolerance to medications that in the investigator's judgment, is medically significant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ataxia</keyword>
	<keyword>SCA</keyword>
	<keyword>Spinocerebellar Ataxia</keyword>
</DOC>